XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
A portion of the Company's non-vested share-based payment awards are considered participating securities and as such, the Company is required to use the two-class method for the computation of basic and diluted earnings per share. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. The non-vested share-based payment awards are not allocated losses as the awards do not have a contractual obligation to share in losses of the Company.
The following is a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for the three months ended March 31, 2022 and 2021:
 Three Months Ended March 31,
 20222021
BASIC  
Net income attributable to common shareholders
$8,989 $39,401 
Weighted-average number of common shares outstanding - basic
283,640,465 275,416,327 
 
Net income attributable to common shareholders - per common share basic
$0.03 $0.14 
DILUTED
Net income attributable to common shareholders - basic
$8,989 $39,401 
Impact of assumed conversions
— 240 
Net income attributable to common shareholders
$8,989 $39,641 
Weighted-average common shares outstanding - basic
283,640,465 275,416,327 
Effect of dilutive securities:
Shares issuable under forward sales agreements
4,348,422 9,843 
Unvested share-based payment awards1,078,891 775,108 
Operating partnership units— 2,852,419 
Weighted-average common shares outstanding - diluted
289,067,778 279,053,697 
Net income attributable to common shareholders - per common share diluted
$0.03 $0.14 
For per common share amounts, all incremental shares are considered anti-dilutive for periods that have a loss from continuing operations attributable to common shareholders. In addition, other common share equivalents may be anti-dilutive in certain periods.